Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Syndax Leverages Novel IP for Cash, Phase II HDAC

This article was originally published in Start Up

Executive Summary

Syndax has parlayed its HDAC/nuclear receptor ligand combo IP into a $40 million Series A backed by Domain and MPM and a licensing deal with Bayer-Schering.

You may also be interested in...



Syndax Begins New Chapter As A Late-Stage Drug Developer

A recent influx of cash to the small biotech will allow Syndax to develop its oncology asset on its own, beginning with a Phase III trial and potentially continuing to U.S. commercialization.

The HDAC Field Heats Up: An Interview with Syndax CEO Joanna Horobin

HDAC Inhibitor Mysteries Remain As Candidates Advance

With more than a dozen candidates in the clinic and a range of indications expanding outside oncology, the histone deacetylase inhibitor class could be poised to make major inroads. But much remains to be learned about the activity, and companies are scrambling to find biomarkers.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel